Unknown

Dataset Information

0

Novel Androgen Deprivation Therapy (ADT) in the Treatment of Advanced Prostate Cancer.

ABSTRACT: Androgen deprivation therapy has been the mainstay of treatment for advanced and metastatic prostate cancer. The use of novel agents targeting the androgen receptor and its signaling pathways offers a promising approach that is both safe and effective. We describe the rationale behind the use of these compounds in clinical development and the existing challenges as to how best to incorporate these new and emerging therapies in the changing treatment paradigm of metastatic prostate cancer.

SUBMITTER: Aragon-Ching JB 

PROVIDER: S-EPMC3172154 | biostudies-literature | 2010 Jul

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Novel Androgen Deprivation Therapy (ADT) in the Treatment of Advanced Prostate Cancer.

Aragon-Ching Jeanny B JB   Dahut William L WL  

Drug discovery today. Therapeutic strategies 20100701 1-2

Androgen deprivation therapy has been the mainstay of treatment for advanced and metastatic prostate cancer. The use of novel agents targeting the androgen receptor and its signaling pathways offers a promising approach that is both safe and effective. We describe the rationale behind the use of these compounds in clinical development and the existing challenges as to how best to incorporate these new and emerging therapies in the changing treatment paradigm of metastatic prostate cancer. ...[more]

Similar Datasets

Unknown Enzalutamide + androgen deprivation therapy (ADT) versus flutamide + ADT in Japanese men with castration-resistant prostate cancer: AFTERCAB study.
| S-EPMC8988761 | biostudies-literature
Unknown Relugolix: a novel androgen deprivation therapy for management of patients with advanced prostate cancer.
| S-EPMC8366106 | biostudies-literature
Unknown Germline predictors of androgen deprivation therapy response in advanced prostate cancer.
| S-EPMC3538410 | biostudies-literature
Unknown Metabolomic effects of androgen deprivation therapy treatment for prostate cancer.
| S-EPMC7286468 | biostudies-literature
Unknown Next-generation sequencing of advanced prostate cancer treated with androgen-deprivation therapy.
| S-EPMC4062940 | biostudies-literature
Unknown Prostate Radiotherapy With Adjuvant Androgen Deprivation Therapy (ADT) Improves Metastasis-Free Survival Compared to Neoadjuvant ADT: An Individual Patient Meta-Analysis.
| S-EPMC8189640 | biostudies-literature
Unknown Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis.
| S-EPMC4911003 | biostudies-literature
Unknown Sarcopenia during androgen-deprivation therapy for prostate cancer.
| S-EPMC3434987 | biostudies-literature
Unknown Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer.
| S-EPMC4477786 | biostudies-literature
Unknown AZGP1 Protein Expression in Hormone-Naive Advanced Prostate Cancer Treated with Primary Androgen Deprivation Therapy.
| S-EPMC7460336 | biostudies-literature